Drugs / ATG-Fresenius S
ATG-Fresenius S
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial · 1 missed | ||||||
| Phase 3 | NCT00655343 | Feb 2003 → Mar 2007 | graft versus host disease | Neovii Biotech | Completed | Missed primary |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT01324934 Comparator | Oct 2006 → Jan 2011 | transplant rejection | Neovii Biotech | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ATG-Fresenius S | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01324934 ↗ |
| Known as | ATG-F | “Here we reanalyzed and updated a randomized phase 3 trial comparing standard GVHD prophylaxis with or without pretransplantation ATG-Fresenius (ATG-F) in 201 adult patients...” PMID 21467544 ↗ Apr 2011 |
| Known as | ATG-Fresenius | “treatment with ATG-Fresenius administered in addition to standard treatment” NCT01324934 ↗ |
| Modality | Protein / enzyme biologic | “20 mg rabbit immunoglobulin (IgG) in 1 ml of sterile solution” NCT00655343 ↗ |
| Route | Intravenous | “slow intravenous infusion at days -3, -2, -1 prior to transplantation” NCT00655343 ↗ |